TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28591081

Group type: EXPERIMENTAL
Intervention: Avoidance pattern
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Pacing pattern
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Overdoing pattern
Number of subjects: 119
Study: 27359058

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 221

Group type: COMPARATOR
Intervention: Fulvestrant 250 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (post-antiestrogen)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (post-aromatase inhibitor)
Number of subjects: 221
Study: 24678612

Group type: EXPERIMENTAL
Intervention: Mosquito repellent and LLINs (Buzz-Off petroleum jelly, essential oil blend applied every evening)
Number of subjects: 6082

Group type: EXPERIMENTAL
Intervention: Mosquito repellent and LLINs
Number of subjects: 6082

Group type: COMPARATOR
Intervention: LLINs alone
Number of subjects: 6082
Study: 22675449

Group type: EXPERIMENTAL
Intervention: Stepping Stones intervention
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Previous rape perpetration
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: First-time rape perpetration
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Re-offending
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Lifetime partners
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Physical violence toward female partner
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Disclosure of rape perpetration at baseline
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Resistance to peer pressure
Number of subjects: 1147
Study: 20173052

Group type: COMPARATOR
Intervention: Home monitoring (HM)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 102
Study: 18854763

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 27
Study: 16446681

Group type: EXPERIMENTAL
Intervention: Bolus treatment (1,000 ml of water immediately before exercise)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intermittent treatment (250 ml of water immediately before exercise and 250 ml at minutes 15, 30, and 45)
Number of subjects: 6
Study: 11874392

Group type: EXPERIMENTAL
Intervention: Levormeloxifene 20-160 mg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Levormeloxifene 2.5-320 mg (single doses)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Levormeloxifene 160 mg (multiple dosing)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Levormeloxifene
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 10509333

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Number of subjects: 15

Group type: COMPARATOR
Intervention: Formocresol
Number of subjects: 15
Study: 8039625

Group type: EXPERIMENTAL
Intervention: Continuous therapy with 6 MU of interferon alfa-2a, three times weekly for 9 months (group 1)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intermittent therapy with 6 MU of interferon alfa-2a for two 3-month cycles separated by a 6-month pause (group 2)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Continuous therapy (group 1)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intermittent therapy (group 2)
Number of subjects: 135
Study: 2905740

Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alpha three times a week for 12 weeks
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 36 million units of interferon alpha three times a week for 12 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alpha
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 36 million units of interferon alpha
Number of subjects: 67
Study: 31899948

Group type: EXPERIMENTAL
Intervention: Water containing 1.8375 × 10^10 cfu/l of probiotics for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Water without probiotics
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Probiotics x week interaction
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Week of supplementation
Number of subjects: 48
Study: 29703157

Group type: EXPERIMENTAL
Intervention: Low educational attainment (6 years or less)
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Blue-collar job history
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Low educational attainment (after adjustment for employment history)
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Former habitual alcohol consumption, medical history of diabetes, Parkinson's disease, stroke, angina pectoris/cardiovascular disease
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Educational attainment
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Occupational history
Number of subjects: 1303

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1303
Study: 28558524

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation (LKM)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Progressive muscle relaxation (active control group)
Number of subjects: 115
Study: 25535142

Group type: EXPERIMENTAL
Intervention: Intracoronary tirofiban administration
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 22339984

Group type: EXPERIMENTAL
Intervention: Self-help manual with standard care and treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care and treatment
Number of subjects: 56
Study: 21075855

Group type: EXPERIMENTAL
Intervention: Men (intervention group)
Number of subjects: 9362

Group type: EXPERIMENTAL
Intervention: Women (intervention group)
Number of subjects: 9362
Study: 17895883

Group type: EXPERIMENTAL
Intervention: Recreational, non‐competitive physical activity program (3 sessions of 90 minutes per week for 24 weeks)
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Recreational, non‐competitive physical activity program
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1044
Study: 15996602

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 2648

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2648
Study: 12074792

Group type: EXPERIMENTAL
Intervention: Bilateral prostatic nerve block prior to biopsy
Number of subjects: 108

Group type: COMPARATOR
Intervention: No nerve block
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Local anaesthesia injection for repeat biopsy
Number of subjects: 108
Study: 10342548

Group type: EXPERIMENTAL
Intervention: Ocular occlusion (early reduced light exposure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No ocular occlusion (standard light exposure)
Number of subjects: 0
Study: 8869329

Group type: EXPERIMENTAL
Intervention: Total gastrectomy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Total gastrectomy and S-shaped gastric substitute
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Gastric pouch or subtotal gastrectomy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Gastric reservoir (total gastrectomy with S-shaped substitute)
Number of subjects: 89
Study: 1565550

Group type: EXPERIMENTAL
Intervention: Myringotomy with tube insertion
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Myringotomy alone
Number of subjects: 220

Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 220
Study: 6338890

Group type: EXPERIMENTAL
Intervention: Self-admission scheme for myocardial infarction
Number of subjects: 511
Study: 30718450

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the associative-limbic subthalamic nucleus (STN)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Off stimulation (control condition)
Number of subjects: 10
Study: 27349461

Group type: EXPERIMENTAL
Intervention: Mindfulness (measured using the Five Facet Mindfulness Questionnaire)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mindfulness facets (Describing, Acting-with-Awareness, Non-judging)
Number of subjects: 80
Study: 26954319

Group type: EXPERIMENTAL
Intervention: DFD‐01 (0.05% betamethasone dipropionate in emollient spray)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 538
Study: 25136645

Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME) for 3 months, including 8 weeks of education and 4 weeks of practice
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard advice on medical nutrition therapy (Control)
Number of subjects: 76
Study: 22955355

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus salivarius LS01 and Bifidobacterium breve BR03)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 48
Study: 20608142

Group type: EXPERIMENTAL
Intervention: 5 ml 2% lidocaine
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 5 ml 2% mepivacaine
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 220
Study: 17470962

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol (discontinued after 6 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 39
Study: 15482535

Group type: EXPERIMENTAL
Intervention: lamivudine 100 mg/day for up to 5 years
Number of subjects: 58
Study: 12133355

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) with 5 min of ischemia and 5 min of reperfusion
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group: simple hepatic blood inflow occlusion (HBIO)
Number of subjects: 29
Study: 9661540

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg during sternotomy and 30 mg/kg during initiation of cardiopulmonary bypass)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 60
Study: 7620696

Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 16
Study: 2123367

Group type: EXPERIMENTAL
Intervention: Moclobemide (100 mg, 6 weeks)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Imipramine (33 mg, 6 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (6 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Moclobemide (52-week assessment)
Number of subjects: 72
Study: 6274592

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid sutures (PGA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyester sutures
Number of subjects: 0
Study: 31390617

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Active control intervention (progressive muscle relaxation and psychoeducation)
Number of subjects: 62
Study: 31002554

Group type: EXPERIMENTAL
Intervention: Local warming at 42ºC for 10 minutes
Number of subjects: 55
Study: 28933799

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 26267747

Group type: EXPERIMENTAL
Intervention: Liposomal prostaglandin E1 (lipo‐PGE1) 20 μg/day diluted in 10 ml of normal saline, administered intravenously over 5 min starting 3 days before PCI and continuing for 4 days after PCI
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Liposomal prostaglandin E1 (lipo‐PGE1)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (normal saline 10 ml administered intravenously)
Number of subjects: 219
Study: 25055027

Group type: EXPERIMENTAL
Intervention: NAP SACC program (treatment group)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 209
Study: 21777507

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP): 50 mg eq. on days 1 and 8, flexible dosing 25-100 mg eq. once-monthly
Number of subjects: 749

Group type: COMPARATOR
Intervention: Risperidone long-acting injectable (RIS-LAI): bi-weekly injections of 25 mg on days 8 and 22, flexible dosing (25-50 mg) starting from day 36
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Both treatments (PP and RIS-LAI)
Number of subjects: 749
Study: 19476477

Group type: EXPERIMENTAL
Intervention: Inhaled TI (25 U)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inhaled TI (50 U)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inhaled TI (100 U)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Subcutaneous RHI (10 IU)
Number of subjects: 11
Study: 17541337

Group type: EXPERIMENTAL
Intervention: Saliva samples
Number of subjects: 274

Group type: COMPARATOR
Intervention: Blood samples
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 274
Study: 15051600

Group type: EXPERIMENTAL
Intervention: High-oleate meal (50 g fat)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: High-palmitate meal (50 g fat)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low-fat meal (15 g fat)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 51
Study: 12113542

Group type: EXPERIMENTAL
Intervention: Gum chewing (chewed three times a day from the first postoperative AM until oral intake)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no gum chewing)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study: 9728846

Group type: EXPERIMENTAL
Intervention: IV amino acid mixture, 240 kJ/h before and during anesthesia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetated Ringer's solution during isoflurane anesthesia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Awake controls (no anesthesia or surgery)
Number of subjects: 24
Study: 7651785

Group type: EXPERIMENTAL
Intervention: Exclusive breast‐feeding with addition of hygienically prepared, nutritionally adequate complementary foods at 4 months
Number of subjects: 141

Group type: COMPARATOR
Intervention: Exclusive breast‐feeding to 6 months
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Honduran infants (n = 141)
Number of subjects: 141
Study: 2491990

Group type: EXPERIMENTAL
Intervention: Short-term administration of Buserelin (day 1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Long-term protocol (day 21)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (13 patients)
Number of subjects: 18
Study: 1120556

Group type: EXPERIMENTAL
Intervention: Perexiline maleate at 400 mg/die
Number of subjects: 16

Group type: COMPARATOR
Intervention: Prenilamine at 120 mg/die
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30102427

Group type: COMPARATOR
Intervention: BUP/SAM 2 mg/2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BUP/SAM at 4-fold (8 mg/8 mg) and 8-fold (16 mg/16 mg) the therapeutic dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine alone (8 mg and 16 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BUP/SAM
Number of subjects: 0
Study: 29045326

Group type: EXPERIMENTAL
Intervention: Exercise (40 min of submaximal high-intensity interval cycling)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Strawberry (25 g freeze-dried strawberries)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (strawberry flavoring)
Number of subjects: 10
Study: 26348160

Group type: EXPERIMENTAL
Intervention: Early value system activated by negative outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late value system responding to outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thalamostriatal pathway interaction
Number of subjects: 0
Study: 23385795

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Moxifloxacin susceptibility
Number of subjects: 500
Study: 21206932

Group type: EXPERIMENTAL
Intervention: NitrAdine tablets
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 18083355

Group type: EXPERIMENTAL
Intervention: High-sugar diet (70% energy from carbohydrate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-fat diet (50% energy from fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-starch diet (70% energy from carbohydrate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-sugar diet
Number of subjects: 12
Study: 17437826

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 655

Group type: COMPARATOR
Intervention: Pubovaginal sling
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Supine empty bladder stress test
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Valsalva leak point pressure measurements
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Medical, Epidemiological and Social Aspects of Aging
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Incontinence Impact Questionnaire
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Urogenital Distress Inventory
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Valsalva leak point pressure
Number of subjects: 655
Study: 15548480

Group type: EXPERIMENTAL
Intervention: 30 g mucuna preparation
Number of subjects: 8

Group type: COMPARATOR
Intervention: LD/CD
Number of subjects: 8
Study: 11305824

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with epinephrine 1:200,000 infiltrations (10 ml into the portals, 10 ml at the medial tibial incision site, 10 ml at the lateral femoral incision site, and 10 ml intra-articularly presurgically; 5 ml at the medial tibial incision and 10 ml at the lateral femoral incision postsurgically)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline 0.9% infiltrations (same administration as treatment group)
Number of subjects: 23
Study: 9158385

Group type: EXPERIMENTAL
Intervention: Trimetazidine treatment started twenty-four hours after percutaneous transluminal coronary angioplasty (PTCA) in 26 patients (Group I)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group without trimetazidine treatment (25 patients, Group II)
Number of subjects: 51
Study: 8502506

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (ANCS)
Number of subjects: 239

Group type: COMPARATOR
Intervention: No antenatal corticosteroids (Control)
Number of subjects: 239
Study: 2437347

Group type: EXPERIMENTAL
Intervention: Dextran sulfate (mild anticoagulant) for 7 to 56 months (average, 25.4 months)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Natural history (conservative management with serial measurements of GFR)
Number of subjects: 246
Study: 31176888

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Present-centered therapy (PCT)
Number of subjects: 200
Study: 28634985

Group type: EXPERIMENTAL
Intervention: Korean version of the Affective Go/No-Go test
Number of subjects: 15

Group type: COMPARATOR
Intervention: English version of the Affective Go/No-Go test
Number of subjects: 15
Study: 27421623

Group type: EXPERIMENTAL
Intervention: Low-dose fluocinolone acetonide implant (FAi)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-dose fluocinolone acetonide implant (FAi)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant (FAi)
Number of subjects: 11
Study: 25042693

Group type: EXPERIMENTAL
Intervention: Sildenafil (20mg 3× daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sildenafil and Placebo
Number of subjects: 22
Study: 23077913

Group type: EXPERIMENTAL
Intervention: Indirect veneers (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct veneers (Group B)
Number of subjects: 0
Study: 20357377

Group type: EXPERIMENTAL
Intervention: Nonremovable fiberglass off‐bearing cast (TCC group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Removable cast walker (Stabil‐D group)
Number of subjects: 45
Study: 18277899

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) for steroid-dependent CD patients
Number of subjects: 44
Study: 16117698

Group type: EXPERIMENTAL
Intervention: Fixed brimonidine/timolol BID (n = 385)
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Brimonidine 0.2% TID (n = 382)
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Timolol 0.5% BID (n = 392)
Number of subjects: 1159
Study: 11967597

Group type: EXPERIMENTAL
Intervention: Selective decontamination of subglottic area (SDSA) using a continuous infusion of a suspension containing polymyxin, tombramycin, and amphotericin B (n=30)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (n=31)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Selective decontamination of subglottic area (SDSA)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 9989716

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (5 mg or 10 mg daily) for 1 month
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 32
Study: 8528370

Group type: EXPERIMENTAL
Intervention: Tacrine treatment for 14 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 20
Study: 2181748

Group type: EXPERIMENTAL
Intervention: Local oestrogen in the vagina
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23
Study: 7351606

Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 28304146

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 26030324

Group type: EXPERIMENTAL
Intervention: Cycle-ergometer exercise at 60% of the patients' maximal oxygen uptake (∼35 W)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy controls (7 subjects)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: McArdle patients during exercise
Number of subjects: 11